Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Bioequivalence of VM-1500FDC vs Elpida + Truvada in Healthy Subjects
NCT03706924Phase 1Completed
- Sponsor
- Viriom Inc
- Start
- Jun 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of elsufavirine in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Viriom Inc. Primary endpoints: Plasma concentration of VM1500A at 29 days, Plasma concentration of elsulfavirine at 29 days and 2 more. Started Jun 2018; status: completed.
02
Drugs
elsufavirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03706924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03706924.